Condition (MeSH)
Li-Fraumeni Syndrome
ClinicalTrials.gov lists 24 trials for Li-Fraumeni Syndrome or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
24 of the 24 trials are tagged with Li-Fraumeni Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Li-Fraumeni Syndrome trials start? (16)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 3 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
Showing 10 of 16 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Li-Fraumeni Syndrome trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Not applicable | 3 |
| Observational | 18 |
How many Li-Fraumeni Syndrome trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 12 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 8 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Li-Fraumeni Syndrome trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 5 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
Which drugs are being tested for Li-Fraumeni Syndrome? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Arsenic Trioxide | 1 |
Interventions as named in the registry (2)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| PET-MRI | 1 |
| 1% Metformin | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Li-Fraumeni Syndrome? (21)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Embodied risk for families with Li-Fraumeni syndrome: Like electricity through my body. | Social science & medicine (1982) | 2022 | Yes |
| Family communication challenges of adolescents and young adults with Li-Fraumeni syndrome: Implications for psychosocial care. | Patient education and counseling | 2022 | Yes |
| Li-Fraumeni Syndrome and Whole-Body MRI Screening: Screening Guidelines, Imaging Features, and Impact on Patient Management. | AJR. American journal of roentgenology | 2021 | Yes |
| Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. | The Lancet. Oncology | 2021 | Yes |
| A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma. | Cells | 2021 | Yes |
Showing 5 of 21 publications.
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Li-Fraumeni syndrome | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Li-Fraumeni syndrome | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Li-Fraumeni syndrome | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Unspecified |
| Li-Fraumeni syndrome | Point prevalence | 1-9 / 100 000 | United States | US | Exact |
| Li-Fraumeni syndrome | Point prevalence | 1-9 / 100 000 | United States | US | Unspecified |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Li-Fraumeni syndrome | 524 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Li-Fraumeni syndrome | 524 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.